{"id":23849,"date":"2026-06-20T10:39:00","date_gmt":"2026-06-20T08:39:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=b4bebbd0c4a7801a533295fed5f073f7"},"modified":"2026-06-20T10:39:00","modified_gmt":"2026-06-20T08:39:00","slug":"greenstone-biosciences-inc-and-intel-corp-launch-strategic-collaboration-to-scale-human-centric-drug-discovery","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=23849","title":{"rendered":"Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery"},"content":{"rendered":"

\nCombining human iPSC biology and AI computing to accelerate drug discovery, improve drug safety, and advance precision medicine.<\/p><\/a><\/a>

PALO ALTO, Calif.--(BUSINESS WIRE)--#AIinbiotech<\/a>--Greenstone Biosciences, Inc.<\/b> announces a collaboration with Intel<\/b> Corp.<\/b> (NASDAQ: INTC)<\/b> to accelerate AI-enabled drug discovery using Greenstone\u2019s<\/b> large-scale, human biobank of induced pluripotent stem cells and Intel\u2019s<\/b> Edge AI<\/b> advanced computing and AI infrastructure. Intel<\/b> and Greenstone<\/b> are working together to speed up the development of new medicines. The collaboration combines state-of-the-art human genetics and biology from Greenstone<\/b> with Intel<\/b> purpose-built silicon \u2013 to scale data processing, storage, and analysis. Greenstone<\/b> has built the world\u2019s largest human biobank of induced pluripotent stem cells (iPSC).<\/p>

\n\u201cThis collaboration represents an important step toward more human-centered drug development,<\/i>\u201d said Joseph C. Wu<\/b>, M.D., Ph.D., Co-Founder of Greenstone<\/b> Biosciences<\/b> and Director of the Stanford Cardiovascular Institute (SCVI). \u201cBy combining our iPSC-based systems with Intel\u2019s<\/b> advanced computing architecture, we identify patient-specific response patterns, improve prediction of adverse drug effects, and advance new medicines more quickly and at a lower cost<\/i>.\u201d<\/p>

\nThe collaboration also supports growing US FDA regulatory momentum toward New Approach Methodologies (NAMs) (FDA Modernization Act 3.0<\/a>) along with biotech and pharmaceutical industries that complement traditional animal studies and improve the translational relevance of preclinical testing. By combining human cellular models, population-scale datasets, and AI-enabled analytics, Greenstone<\/b> and Intel<\/b> aim to help advance the next generation of drug safety assessment and new medicines.<\/p>

\nFor a replay of Intel\u2019s<\/b> Computex <\/b>2026 keynote address, highlighting collaboration with Greenstone<\/b>, click here: link<\/a>, video<\/a>, (57:45)<\/p>

\nLearn more about the implementation and opportunities for NAMs in drug discovery and development here: Wu et al., 2026; Science<\/a>, Liu et al., 2026; Cell<\/a>, Herron et al., 2025; Nature<\/a>.<\/p>

\nAbout Greenstone Biosciences, Inc<\/b>.<\/p>

\nGreenstone Biosciences, Inc<\/b>. (Silicon Valley, CA) is a biotechnology company based in the Stanford Research Park and co-founded by Joseph C. Wu, M.D., Ph.D.<\/a> (Professor & Director of Stanford Cardiovascular Institute). Greenstone<\/b> is funded by Walden Catalyst, Mayfield, Prosperity 7 Ventures, and others. The company specializes in New Approach Methodologies (NAMs), clinical genomics, iPSC platform, artificial intelligence\/machine learning, and drug development. Greenstone<\/b> has extensive expertise in generating patient-derived human organoids for disease modeling and drug discovery. https:\/\/greenstonebio.com<\/a><\/p> Contacts<\/b>

\nFor more info, please contact Jade T. Chao<\/b>, JD, MPH at jadechao@greenstonebio.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Combining human iPSC biology and AI computing to accelerate drug discovery, improve drug safety, and advance precision medicine.PALO ALTO, Calif.–(BUSINESS WIRE)–#AIinbiotech–Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. (…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-23849","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/23849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23849"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/23849\/revisions"}],"predecessor-version":[{"id":23850,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/23849\/revisions\/23850"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}